Leukotriene modifier drug label change requested by FDA - MPR

Links shared publicly online about this topic.

1,965
total visits

Leukotriene modifier drug label change requested by FDA - MPR

The FDA has requested that manufacturers of leukotriene modifiers include a precaution in the drug labeling regarding neuropsychiatric events that have been reported in some patients taking montelukast (Singulair, from Merck), zafirlukast (Accolate, from AstraZeneca) and zileuton (Zyflo CR from Cornerstone Therapeutics).

View full resource at empr.com

Tags: Asthma Medication, Drug, FDA, Singulair, AstraZeneca, Merck & Co.

Most Recently Shared on June 16, 2009 at 6:39 pm By:

MPR

MPR News: Leukotriene modifier drug label change requested by FDA: The FDA has requested that manufactu.. http://tinyurl.com/nbs7rz

3 years ago...

Retweet

Favorite

Singulair Side Effects - Will Singulair Side Effects or Side Effects of Other Leukotriene Modifiers Affect Your Mental Health

asthma.about.com — “The FDA preforms surveillance of side effects after drugs have been released for use. Singulair and other leukotriene modifiers have changed their labeling to reflect some potential side effects with this class of drugs.” View full resource at asthma.about.com